3 Reasons Aphria (TSX:APHA) Stock Is Looking Better Than Ever

With its larger competitors beginning to stall out, Aphria Inc (TSX:APHA)(NYSE:APHA) is looking better than ever

| More on:

Aphria Inc (TSX:APHA)(NYSE:APHA) has long been one of the more controversial marijuana stocks. Between short attacks, shareholder lawsuits, and a hostile takeover bid, the company has been involved in more drama than any of the other major weed producers. As a result of the bad press, Aphria was once among the most hated weed companies.

Now, however, with Canopy Growth Corp (TSX:WEED)(NYSE:CGC) losing money and other producers stalling out, it’s beginning to look like one of the best in its class. The following are just three reasons why Aphria stock is looking better than ever.

The fastest-growing weed producer

The most obvious thing that will stand out in Aphria’s third quarter earnings report is the incredible growth. At 617% year-over-year, it exceeds any other weed producer and puts the company within striking distance of Canopy’s sales figures. While Aphria’s recreational sales fell 35%, that was more than made up for by medical and revenue generated by new acquisitions: CC Pharma and ABP. Now, Aphria is just a smidgen smaller than Aurora–and a whole lot cheaper.

Last year’s drama completely resolved

Aphria’s stock suffered last year due to the highly publicized controversies it had been embroiled in. Now, it looks like it’s smooth sailing ahead. As previously mentioned, Aphria’s latest report revealed that much of its revenue is coming from new acquisitions CC Pharma and ABP–completely undermining the claim that such acquisitions had been worthless.

Additionally, most of the high-profile investors who had been short APHA have closed out their positions, so the “short attack” threat is no longer a factor. Finally, while the class-action lawsuit against Aphria appears to be going ahead, the company’s relative success in recent quarters could result in a favourable outcome for the company.

Larger competitors running into problems

A final factor making Aphria look good right now is the competitive landscape in the cannabis space. Simply put, many of Aphria’s competitors aren’t doing so well, which makes Aphria look good by comparison.

Case in point: Canopy Growth. In its most recent quarter, that company posted a $323 million net loss and a $174 million operating loss. In its full year results, it posted a $670 million loss. This is a company that’s burning through cash at a frightening pace–so much so that the markets aren’t rewarding its revenue growth.

The problems with Canopy recently got so bad that the company’s biggest investor publicly stated they were “not pleased” with their results–and may have instigated the ouster of CEO Bruce Linton.

In an industry in which disappointing results are becoming the norm, Aphria’s red-hot growth stands out. It should be noted that Aphria itself is running net losses, but they’re much smaller as a percentage of revenue than Canopy’s.

Additionally, Aphria has posted positive earnings in several quarters, thanks in no small part to its long-term investment portfolio, which may make Aphria look increasingly appealing as investors get hungry for earnings.

Fool contributor Andrew Button has no position in any of the stocks mentioned.

More on Cannabis Stocks

four people hold happy emoji masks
Dividend Stocks

Wary of Mining Companies? A Lower-Risk Way to Get in on the Gold and Silver Surge

Frenco-Nevada (TSX:FNV) stock might be a wiser way to play the run in gold prices this year.

Read more »

Cannabis smoke
Cannabis Stocks

Have Cannabis Stocks Totally Gone Up in Smoke?

Let's dive into whether Canadian cannabis stocks are still investable, and what investors should make of the recent volatility in…

Read more »

Researcher works in hemp field
Cannabis Stocks

1 Undervalued Cannabis Stock to Buy and Hold Over the Next Decade

Green Thumb is a beaten-down cannabis stock that trades at a compelling valuation in September 2025.

Read more »

Researcher works in hemp field
Cannabis Stocks

Pot Stocks Rallied Hard in August: Is There More to Come?

Tilray Brands (TSX:TLRY) and the broad basket of pot stocks could heat up from here.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Canopy Growth Stock Jumped 30% Last Month: What’s Going on?

Canopy Growth (TSX:WEED) stock is picking up traction again, making it an enticing weed play to buy on strength.

Read more »

A cannabis plant grows.
Cannabis Stocks

These Threats Facing Canopy Growth Stock Could Justify Selling it

Let's dive into whether Canopy Growth (TSX:WEED) is a top stock investors should buy right now after its recent dip…

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

This BioCannabis Firm Could Explode with Product Approval

This cannabis stock used to be a major name, so where does it stand now?

Read more »

Medicinal research is conducted on cannabis.
Stocks for Beginners

This TSX Health-Care Stock Is a Long-Term Buy for Patient Investors

This TSX stock continues to be one of the best long-term opportunities, if you're patient.

Read more »